5th Ocular Diseases & Drug Development
|
Register
2,
the 3rd goes free with the coupon code
rcdvb! |
|
|
|
Dear Colleague,
The Ocular Diseases & Drug Development Conference taking place on March
21-22, 2013 in San Francisco, CA is now in its fifth year. As chairperson
and moderator, I look forward to attending this conference. It continues to
offer presentations on novel and innovative therapeutics in ocular drug
development and discovery. This year we are fortunate to have Dr. Samir Patel,
CEO and President of Ophthotech, as our keynote speaker. A leader in the field,
Dr. Patel, a trained retina specialist, will present data from his recent
clinical studies on a new and adjunct treatment for wet AMD, Fovista. We have
two panels at this year's conference: 1) a safety regulatory panel with experts
in the field being moderated by Dr. Ken Mandell and 2) a VC/ BD panel being
moderated by Dr. Emmett Cunningham. This forum allows for excellent networking,
the exchange of ideas, and sharing of challenges; all with a united common goal
of bringing new and innovative treatments to patients in the area of
ophthalmology.
The conference features the following topics:
Session: Novel Targets, Developments and Technologies
Session: Novel Drug Delivery Methods to the Anterior and Posterior Segments
Session: Clinical Development Advances & Updates
Session: Safety Assessment and Regulatory Landscape in Ocular Drug Development
Session: Short Presentations
Panel Discussion: BD, Investments and Potential for Collaborations
Panel Discussion: Safety and Regulatory in Ocular Development
Sponsorship and exhibiting opportunities are available and can be tailored to
fit your needs. Please contact 626-256-6405 x102 or
spex@gtcbio.com
for more information.
The Ocular Diseases & Drug Development Conference promotes the
discovery of ocular disease drug development by bringing together leading
scientists, researchers and experts to discuss and collaborate on the latest
research and development, safety assessment, regulatory issues and drugs in
development for combating and curing age-related macular degeneration (AMD),
diabetic retinopathy, glaucoma, DME, uveitis and other ocular diseases. 2012's
conference was well attended by key R&D delegates from GSK, Pfizer, B&L,
Allergan and Alcon. This year's conference promises to be even bigger and
better. See you there!
Kind Regards,
Barbara Wirostko, M.D.
Chief Scientific Officer and Co-Founder, Jade Therapeutics
Clinical Adjunct Associate Professor, Ophthalmology, University of Utah
|
|
PLATINUM SPONSOR |
|
RECEPTION SPONSOR |
 |
|
|
|
GOLD SPONSORS |
 |
|
|
 |
|
 |
|
 |
|
 |
|
|
MEDIA PARTNERS |
|
 |
|
 |
|
|
 |
Attend ALL GTC Conferences for One Year
for only $3,995 ($1,990 for Acad/Govt).
Click
here to sign up! |
What Past Delegates Said About the Event:
"The GTC Ocular Diseases and Drug Development meeting was highly informative,
covered a wide range of novel technologies and therapeutic areas across the
spectrum of ocular diseases. Moreover, owing to its size, the meeting was ideal
for networking with scientists from the Pharmaceutical industry and academia. I
will definitely be back next year."
- Suliman Al-Fayoumi, Ph.D., M.B.A., Director, Pharmacology, Acucela Inc.
"This was a well run meeting that provided an opportunity to meet new people and
to learn new ideas that might help me advance my own research. It was a
productive and enjoyable experience."
- Carol Toris, Ph.D., Director, Glaucoma Research, University of Nebraska
Medical Center
“I have to congratulate GTC for organizing an excellent conference on Ocular
Drug Development. This conference brought together key opinion leaders involved
in ocular drug development from both academia and industry to discuss some of
the major issues such as those involving formulation, drug delivery and
predictive validity of pre-clinical disease models.”
- M. (Ken) Kengatharan, Ph.D.,M.B.A., President & CSO, Altheos, Inc.
"GTC's Ocular Disease and Drug Development meeting was perfectly orchestrated,
providing a nice balance of science and innovation with targeted networking
opportunities in the ophthalmology field."
- Christopher Stanley Chief Business Officer RxGen, Inc.
“Among all the meetings I attend, I really enjoy and look forward to the GTC
Ocular Diseases and Drug Development conference every year. It is a meeting that
allows for open discussions about ophthalmic drug development, challenges in
research and clinical trials and innovations. It is a conference driven by
research and common goals. It has been a pleasure to be involved and it is very
rewarding to see so many exceptional innovators in the field participating and
attending.”
-
Barbara Wirostko, Chief Scientific Officer and Co-Founder, Jade Therapeutics;
Clinical Adjunct Associate Professor, Ophthalmology, University of Utah |
|
|
